Boehringer Ingelheim, a leading global pharmaceutical company, is headquartered in Ingelheim am Rhein, Germany. Founded in 1885, the company has established a strong presence in the healthcare industry, focusing on human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. With a commitment to innovation, Boehringer Ingelheim is renowned for its core products, including treatments for respiratory diseases, cardiovascular conditions, and diabetes management. The company’s dedication to research and development has led to significant milestones, positioning it among the top pharmaceutical firms worldwide. Notable achievements include a robust pipeline of novel therapies and a strong market presence in Europe, North America, and Asia. Boehringer Ingelheim continues to enhance its reputation through its unique approach to healthcare solutions, prioritising patient needs and sustainable practices.
How does Boehringer Ingelheim's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Boehringer Ingelheim's score of 34 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Boehringer Ingelheim reported global carbon emissions of approximately 295,000,000 kg CO2e for Scope 1 and about 66,000,000 kg CO2e for Scope 2. The company has set ambitious targets to reduce its greenhouse gas emissions, committing to a 58.9% reduction in absolute Scope 1 and 2 emissions by 2030, using 2019 as the base year. Additionally, Boehringer Ingelheim aims for a 27.5% reduction in absolute Scope 3 emissions, which encompass emissions from purchased goods and services, capital goods, and other related activities, within the same timeframe. In the UK, for 2022, Boehringer Ingelheim's emissions were reported at approximately 1,116,000 kg CO2e, with Scope 1 emissions at about 655,000 kg CO2e and Scope 3 emissions at around 461,000 kg CO2e. The company has disclosed emissions data across all three scopes, demonstrating a comprehensive approach to its climate commitments. Boehringer Ingelheim's targets are aligned with the Science Based Targets initiative (SBTi), ensuring that their reduction goals are consistent with the global aim to limit warming to 1.5°C. The company’s emissions data is cascaded from its parent organization, Boehringer Ingelheim GmbH, reflecting a unified corporate strategy towards sustainability and climate action.
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 289,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 273,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 3,801,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Boehringer Ingelheim has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


Common questions about Boehringer Ingelheim's sustainability data and climate commitments